HRT2-150 | Difference (95% CI) | ||||
---|---|---|---|---|---|
yes | no | ||||
Number | 55 | 420 | |||
Age | |||||
Median | 61 | 68 | |||
Interquartile range | 57–66 | 64–72 | |||
BMI† | |||||
Median | 27.5 | 28.2 | |||
Interquartile range | 24.7–30.2 | 25.7–31.6 | |||
Age at menopause‡ | |||||
Median | 51 | 50 | |||
Interquartile range | 50–54 | 48–53 | |||
Prevalence of (%) | |||||
Current smoking | 10.9 | 4.8 | 6.1 (−2.3 to 14.6) | ||
Former smoking | 18.2 | 18.8 | −0.6 (−11.5 to 10.2) | ||
Diabetes mellitus§ | 1.8 | 10.5 | −8.7 (−13.3 to −4.1) | ||
Gout¶ | 14.5 | 10.3 | 4.2 (−5.5 to 14.0) | ||
Thiazide intake | 14.4 | 19.8 | −5.4 (−15.3 to 4.8) | ||
Hysterectomy | 41.8 | 27.6 | 14.2 (0.5 to 27.9) |
↵2-150 Use of hormone replacement therapy. †Body mass index (kg/m2). ‡Based on 347 women with available information on age at menopause. §History of diabetes or use of oral antidiabetics or insulin. ¶History of gout or use of uricosurica/uricostatica.